Form 4: Elanco Animal Health Executive Todd S. Young Reports Stock and Option Grants

Todd S. Young, Executive Vice President and CFO of Elanco Animal Health, reports the acquisition of restricted stock units and stock options.

Summary

• On March 3, 2025, Todd S. Young, Executive Vice President and Chief Financial Officer of Elanco Animal Health Inc., reported transactions involving Elanco's common stock and derivative securities.
• Young acquired 64,103 shares of common stock through a grant of restricted stock units, which vest in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028.
• He also acquired 134,509 stock options with an exercise price of $11.31, vesting in the same manner as the restricted stock units and expiring on March 3, 2035.
• Additionally, Young disposed of 200,969 shares of common stock.
• Following these transactions, Young directly owns 134,509 stock options and indirectly owns shares through an IRA (6,562 shares), J.G. Young IRA (2,000 shares), UTMA accounts for his daughter and son (5,500 shares each), and a Living Trust (149,308 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants, with a slight negative due to the disposal of shares, but overall, it's an expected event.

Positives

• The grant of restricted stock units and stock options to a key executive like the CFO can be seen as a positive sign, aligning his interests with the long-term performance of the company.

Negatives

• The disposal of 200,969 shares of common stock by Young could be interpreted negatively by some investors, although the reason for the disposal is not specified.

Risks

• The vesting schedule of the restricted stock units and stock options means that the executive's compensation is tied to the company's performance over the next several years, which could incentivize short-term decision-making.

Future Outlook

The vesting schedule of the restricted stock units and stock options indicates a multi-year commitment by the executive to the company's future performance.

Industry Context

Executive compensation in the animal health industry often includes stock options and restricted stock units to align management's interests with shareholder value. This filing is a routine disclosure of such compensation.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common compensation practices among publicly traded animal health companies such as Zoetis and IDEXX Laboratories.
• The vesting schedules and exercise prices are generally in line with industry norms for executive compensation packages.

Stakeholder Impact

• Shareholders may be interested in the details of executive compensation and its alignment with company performance.
• Employees may view the stock and option grants as a sign of the company's commitment to its leadership.

Key Dates